Tag: ADT
-
Shorter Hormone Therapy May Suffice for Prostate Cancer
New findings suggest shorter hormone therapy could be enough for many men with prostate cancer For years, androgen deprivation therapy (ADT) has been a mainstay in treating prostate cancer, often prescribed for extended periods to slow tumor growth. But a new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center points to…
-
Shorter Hormone Therapy May Be Sufficient for Many Prostate Cancer Patients
New Insights on Hormone Therapy Duration for Prostate Cancer Androgen deprivation therapy (ADT) has long been a cornerstone in the treatment of prostate cancer. A landmark study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests that many men may not need prolonged hormone therapy. The findings indicate that the majority of…
-
Shorter Hormone Therapy May Be Enough for Many Men with Prostate Cancer
New Insights into Hormone Therapy for Prostate Cancer When managing prostate cancer, androgen deprivation therapy (ADT) has long been a standard approach to slow tumor growth by lowering testosterone levels. A recent study, co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center, points to a pivotal shift in how clinicians may approach the…
-
Radiopharmaceutical Therapy Boosts Radiation to Slow Prostate Cancer
New Findings from the LUNAR Trial A landmark phase II study, known as the LUNAR trial, reports that people with recurrent prostate cancer and a limited number of metastases lived significantly longer without disease progression when a radiopharmaceutical drug was given before targeted radiation therapy, compared with high-precision radiation alone. The randomized study evaluated whether…